
Cytophage Technologies Ltd. — Investor Relations & Filings
Cytophage Technologies Ltd. is a pioneering biotechnology company focused on developing synthetic bacteriophage products to prevent and treat bacterial infections, aiming to reduce and ultimately replace the use of conventional antibiotics. The company utilizes molecular genetic techniques and proprietary synthetic biology technology to create tailor-made, highly effective phages that are harmless to humans and animals. Cytophage's solutions address three primary markets: Animal Health (e.g., livestock illness prevention and growth enhancement), Food Safety (preventing disease spread without antibiotics), and Human Health (treating bacterial illnesses and hospital decontamination). A key competitive advantage is the rapid production timeline for targeted phages, enabling quick response to bacterial threats. The company is also engaged in advanced research, including the development of genetically engineered phage-based vaccines.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| News release - English.pdf | 2026-04-15 | English | |
| Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | |
| News release - English.pdf | 2025-11-29 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 34546772 | News release - English.pdf | 2026-04-15 | English | ||
| 34543854 | News release - English.pdf | 2026-04-15 | English | ||
| 34538131 | News release - English.pdf | 2026-04-15 | English | ||
| 34534051 | News release - English.pdf | 2026-04-15 | English | ||
|
2025
11 filings
| |||||
| 32366236 | Report of exempt distribution (45-106F1).pdf | 2025-12-08 | English | ||
| 32363854 | News release - English.pdf | 2025-11-29 | English | ||
| 32352508 | News release - English.pdf | 2025-11-05 | English | ||
| 32344908 | News release - English.pdf | 2025-10-16 | English | ||
| 32315686 | Report of exempt distribution (45-106F1) (amended).pdf | 2025-09-15 | English | ||
| 32261461 | News release - English.pdf | 2025-07-28 | English | ||
| 13802110 | Report of exempt distribution (45-106F1).pdf | 2025-06-19 | English | ||
| 13800113 | News release - English.pdf | 2025-06-11 | French | ||
| 13796113 | News release - English.pdf | 2025-05-30 | English | ||
| 13796136 | Interim MD&A - English.pdf | 2025-05-30 | English | ||
| 13796135 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2025-05-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Biomind Labs
Developing novel pharmaceutical drugs for patients with neu…
|
BMND | CA | Professional, scientific and te… |
|
BioNexus Gene Lab Corp
Develops gene-based diagnostics for early detection of dise…
|
BGLC | US | Professional, scientific and te… |
|
Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-rela…
|
ALBPS | FR | Professional, scientific and te… |
|
BioRestorative Therapies, Inc.
Develops adult stem cell therapies for degenerative disc an…
|
BRTX | US | Professional, scientific and te… |
|
BioSenic SA
Develops therapies for autoimmune diseases, inflammation, a…
|
BIOS | BE | Professional, scientific and te… |
|
BIOTECH
A biotechnology group offering preclinical services, intein…
|
BST | ES | Professional, scientific and te… |
|
BIOTRON LIMITED
Clinical-stage developer of small molecule antiviral drugs …
|
BIT | AU | Professional, scientific and te… |
|
BioVaxys Technology Corp.
Clinical-stage biopharma developing novel immunotherapy ass…
|
BIOV | CA | Professional, scientific and te… |
|
Biovica International B
Develops blood-based biomarker assays for cancer therapy mo…
|
BIOVIC | SE | Professional, scientific and te… |
|
Boji Medical Technology Co., Ltd.
A CRO providing full-service pharmaceutical and medical dev…
|
300404 | CN | Professional, scientific and te… |
Cytophage Technologies Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48283/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48283 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48283 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48283 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48283}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Cytophage Technologies Ltd. (id: 48283)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.